Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
75 hedge funds and large institutions have $197M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 8 closing their positions.
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
65% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 17
57% more capital invested
Capital invested by funds: $125M → $197M (+$71.7M)
56% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $665K
34% more funds holding
Funds holding: 56 → 75 (+19)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$11.4M |
| 2 |
O
OrbiMed
New York
|
+$6.61M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.61M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$4.73M |
| 5 |
Millennium Management
New York
|
+$4.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.59M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3M |
| 4 |
DM
Deerfield Management
New York
|
-$2.51M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.45M |
FOMX Hedge Fund Activity: Q3 2018 in Review
75 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q3 2018, worth a combined $197M — up 57% from $125M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new FOMX positions and 8 closed out — a net gain of 19 holders — while 28 added to existing stakes and 17 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $11.4M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.59M.
- 75 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q3 2018, up from 56 in Q2 2018.
- Funds reported $197M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q3 2018, up 57% quarter-over-quarter.
- 27 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q3 2018 and 8 closed out, a net change of +19 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q3 2018 was Perceptive Advisors, an estimated $11.4M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q3 2018 was Baker Bros. Advisors, an estimated $4.59M sold.
Based on aggregated 13F filings for Q3 2018.